Price (delayed)
$2.46
Market cap
$43.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.27
Enterprise value
$42.45M
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product ...
Highlights
The EPS has grown by 34% year-on-year
NVNO's debt is down by 24% YoY and by 7% from the previous quarter
enVVeno Medical's net income has increased by 7% YoY but it has decreased by 2.7% from the previous quarter
NVNO's quick ratio is down by 39% YoY and by 5% QoQ
The equity has declined by 11% since the previous quarter and by 9% year-on-year
Key stats
What are the main financial stats of NVNO
MarketValuationsEarnings
Shares outstanding
17.54M
Market cap
$43.14M
Enterprise value
$42.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.02
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$23.83M
Net income
-$21.82M
EBIT
-$21.82M
EBITDA
-$21.29M
Free cash flow
-$16.88M
Per shareBalance sheetLiquidity
EPS
-$1.27
EPS diluted
-$1.27
Free cash flow per share
-$0.98
Book value per share
$2.4
Revenue per share
$0
TBVPS
$2.62
Total assets
$44.95M
Total liabilities
$2.8M
Debt
$1.06M
Equity
$42.16M
Working capital
$41.64M
Debt to equity
0.03
Current ratio
20.88
Quick ratio
20.6
Net debt/EBITDA
0.03
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.2%
Return on equity
-51.2%
Return on invested capital
-56.7%
Return on capital employed
-50.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVNO stock price
How has the enVVeno Medical stock price performed over time
Intraday
-0.81%
1 week
-10.55%
1 month
-18.27%
1 year
-52.23%
YTD
-18.54%
QTD
-6.46%
Financial performance
How have enVVeno Medical's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.83M
Net income
-$21.82M
Gross margin
N/A
Net margin
N/A
NVNO financials
enVVeno Medical's net income has increased by 7% YoY but it has decreased by 2.7% from the previous quarter
enVVeno Medical's operating income has increased by 6% YoY
Growth
What is enVVeno Medical's growth rate over time
NVNO growth chart
Valuation
What is enVVeno Medical stock price valuation
P/E
N/A
P/B
1.02
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has grown by 34% year-on-year
Price to book (P/B)
The price to book (P/B) is 63% lower than the 5-year quarterly average of 2.8 and 26% lower than the last 4 quarters average of 1.4
The equity has declined by 11% since the previous quarter and by 9% year-on-year
Price to sales (P/S)
Efficiency
How efficient is enVVeno Medical business performance
NVNO's ROE is up by 27% year-on-year but it is down by 5% since the previous quarter
The company's return on assets rose by 26% YoY but it fell by 4.8% QoQ
The ROIC has grown by 22% YoY but it has contracted by 4.8% from the previous quarter
Dividends
What is NVNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVNO.
Financial health
How did enVVeno Medical financials performed over time
Assets vs liabilities
NVNO's quick ratio is down by 39% YoY and by 5% QoQ
enVVeno Medical's current ratio has decreased by 39% YoY and by 5% from the previous quarter
Debt vs equity
NVNO's debt is 97% less than its equity
The company's debt to equity has surged by 50% QoQ
NVNO's debt is down by 24% YoY and by 7% from the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.